Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00 at Canaccord Genuity Group

Zevra Therapeutics (NASDAQ:ZVRA) had its price target hoisted by Canaccord Genuity Group from $23.00 to $25.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also weighed in on ZVRA. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday. Finally, Guggenheim increased their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $22.14.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $7.94 on Thursday. The firm has a market cap of $423.81 million, a PE ratio of -4.03 and a beta of 1.98. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business has a 50 day moving average of $7.93 and a 200-day moving average of $8.14. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. As a group, sell-side analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock valued at $674,176 over the last three months. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth $53,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth $94,000. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics in the third quarter worth $94,000. Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter worth $95,000. Finally, Squarepoint Ops LLC raised its position in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after purchasing an additional 4,384 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.